COSCIENS Biopharma Inc. (CSCIF) stock
CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
$6.49+0.00 (0.00%)
Close on Oct 19, 2026Market cap $24.10MP/E –Yield –
COSCIENS Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
COSCIENS Biopharma's operating income for the twelve months ending Mar 31, 2026 was -$7.79M. For fiscal 2025 it was -$10.68M. The highest annual figure on record is $9.84M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.68M | – |
| FY2024 | Dec 31, 2024 | -$18.28M | – |
| FY2023 | Dec 31, 2023 | -$4.63M | -207.2% |
| FY2022 | Dec 31, 2022 | $4.32M | – |
| FY2021 | Dec 31, 2021 | -$8.67M | – |
| FY2020 | Dec 31, 2020 | -$5.71M | – |
| FY2019 | Dec 31, 2019 | -$10.24M | -204.1% |
| FY2018 | Dec 31, 2018 | $9.84M | – |
| FY2017 | Dec 31, 2017 | -$23.07M | – |
| FY2016 | Dec 31, 2016 | -$29.48M | – |
| FY2015 | Dec 31, 2015 | -$34.88M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | -$730.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.39M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.32M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.35M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.66M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.41M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.76M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.81M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.04M | -113.1% |
| Q3 FY2023 | Sep 30, 2023 | -$1.11M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.21M | – |
| Q4 FY2022 | Dec 31, 2022 | $15.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.72M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.81M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.13M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.05M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.16M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.33M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.25M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.74M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.44M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.28M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.76M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.81M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.73M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.94M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.04M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.01M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.50M | – |
See a number that looks wrong?